Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| NOAH HOLDING | NOAH | 9.92% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Human Genome Sciences Inc. ( ) announced that it intends to sell up to 12.5 million shares to raise money for the development of its potential blockbuster lupus drug Benlysta and other business activities.
The net proceeds from the public offering will be used for general corporate purposes, which include the acquisition of additional manufacturing capacity and development of new indications for Benlysta. The underwriters of the offering have a 30-day option to purchase another 1.9 million shares to cover over-allotments.
Human Genome forecasted its operating expenses, after collaboration partner reimbursements, to increase from $250 million in 2009 to a range of about $325 million- $375 million in 2010. The increase is primarily attributable to the pre-launch manufacturing expenses associated with Benlysta coupled with increased sales and marketing expenses.
As a reminder, in November 2009, Human Genome and GlaxoSmithKline ( GSK - Analyst Report ) announced that Benlysta, which they agreed to co-develop and commercialize in August 2006, met the primary end-point in BLISS-76, a pivotal late-stage study, through 52 weeks. BLISS-76 is the second phase III trial in seropositive patients with systemic lupus erythematosus (SLE). Positive results from the first trial, BLISS-52, were announced earlier this year. Benlysta is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocytestimulator (BLyS).
The positive data from the Bliss-76 study brings the company a step closer to being the first to have a new lupus drug approved in 50 years. Lupus affects about 1.5 million people in the United States and 5 million people worldwide. The company intends to file a Biologics License Application (BLA) in the United States in the first half of 2010. We expect US approval in early 2011. If approved, we expect Benlysta to become a blockbuster for the company.
Currently, we are Neutral on Human Genome Sciences.
Read the full reports :
Analyst Report on GSK